Spyre Therapeutics Inc（SYRE）财务数据SYRESpyre Therapeutics Inc

Evaluating the bottom line, Spyre Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.52%, provide a clear picture of how effectively SYRE converts its operational activities into shareholder value.

In the context of the broader market, SYRE competes directly with industry leaders such as IONS and ALKS. With a market capitalization of $8.43B, it holds a leading position in the sector. When comparing efficiency, SYRE's gross margin of N/A stands against IONS's 98.98% and ALKS's 75.67%. Such benchmarking helps identify whether Spyre Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Spyre has demonstrated substantial long-term growth, with a 1-year change of +240.14%. However, it has consistently reported negative net income, with losses reaching -69 million in Q1 2026 and an EPS of -0.36 in the last earnings report, which was a surprise of 49.30%.